Investors

News & Publications

Investors

Investor Relations

Corporate Profile

Arvinas is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses their proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC™ protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

Price
Change
Volume
News Releases
August 7, 2019
NEW HAVEN, Conn. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the company is scheduled to present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday,
July 29, 2019
NEW HAVEN, Conn. , July 29, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today the appointment of Ronald Peck , M.D. to the newly created position of Chief Medical Officer (CMO). Dr.